Endolymphatic sac tumour. Credit: Ed Uthman.

Boston Biomedical has dosed the first patient in a Phase l clinical trial to test the safety and pharmacokinetic of intravenously administered DSP-0509 to treat adults with advanced solid tumours.

The open-label, multicentre trial intends to enrol 44 patients with advanced solid tumours that are refractory to standard treatment.

It will comprise two stages; an initial dose-escalation phase that will use a 3+3 design to establish the maximum tolerated dose, and a dose-expansion phase in up to 14 additional subjects.

As part of the trial, patients will initially receive an intravenous dose of DSP-0509 once a week in induction phase, and once every two weeks in a maintenance phase.

Based on the success of these doses, Boston Biomedical plans to continue treatment until disease progression.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We are looking forward to exploring the safety and activity of DSP-0509 and understanding more about its potential in treating cancer.”

The trial’s primary goals are maximum tolerated dose, identification of Recommended Phase 2 Dose (RP2D), as well as incidence of adverse events (AEs), serious AEs (SAEs), and immune-related AEs (irAEs).

Its secondary goals include pharmacokinetics, objective response rate (ORR), duration of response (DoR), progression-free survival (PFS) and others.

The trial is currently being carried out at various sites in the US.

Boston Biomedical CEO Patricia Andrews said: “We are looking forward to exploring the safety and activity of DSP-0509 and understanding more about its potential in treating cancer.”

DSP-0509 is currently being studied as a synthetic Toll-like receptor (TLR) 7 agonist.

In preclinical settings, DSP-0509 showed its potential to promote the cytokine induction and cytotoxic T lymphocyte (CTL) activation through agonistic effect of TLR 7 expressed in plasmacytoid dendritic cells.